title: [Treatment of essential mild-to-moderate arterial hypertension with once-daily penbutolol. Controlled clinical study vs atenolol].
abstract: The anti-hypertensive and tolerance of penbutolol, a non-selective beta-blocker of long duration and endowed with an ISA effect were compared with those of atenolol, a cardioselective beta-blocker without ISA effect, in two groups of 20 patients each suffering from slight-to-moderate essential primary hypertension selected on the basis of a clinico-experimental design of open randomised type. The two drugs presented a similar anti-hypertensive effect which attained its peak expression in the second week of treatment. As for side-effects, penbutolol during treatment presented better tolerance than atenolol. Further, both penbutolol administered once daily at a dose of 40 mg/die, and atenolol, administered once daily at a dose of 100 mg/die proved to possess satisfactory anti-hypertensive activity justifying its use in a single daily dose.
authors.affiliation: Università degli Studi di Siena - Istituto di Semeiotica Medica.
authors.forename: R
authors.initials: R
authors.lastname: Nami
authors.forename: M
authors.initials: M
authors.lastname: Martinelli
authors.forename: C
authors.initials: C
authors.lastname: Bianchini
authors.forename: C
authors.initials: C
authors.lastname: Gennari
mesh_terms: D000328:Adult; D000368:Aged; D001262:Atenolol / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D001794:Blood Pressure / Q000187:drug effects; D002986:Clinical Trials as Topic; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010394:Penbutolol / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology; D011412:Propanolamines / Q000008:administration & dosage*; D011897:Random Allocation
chemical_list: D011412:Propanolamines; D001262:Atenolol; D010394:Penbutolol
vernacular_title: Trattamento della ipertensione arteriosa essenziale di grado lieve-moderato con penbutololo "once daily". Studio clinico controllato vs atenololo.